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T

he nonobese diabetic (NOD) mouse models the pathogenesis
of human type 1 diabetes and allows the study of potential
therapeutics (1). In NOD mice, the thymic-derived CD4⫹CD25⫹
regulatory T cells (T regs) expressing the transcription factor
Foxp3 suppress autoimmunity and delay the development of
diabetes (2). Considerable effort has focused on expanding the
small numbers of these so-called ‘‘natural’’ CD4⫹CD25⫹ T regs
in the NOD and other models (3–6). Dendritic cells (DCs) are
specialized antigen-presenting cells (APCs) that can effectively
expand and sustain antigen-specific CD4⫹CD25⫹ T regs (3, 4).
However, in humans, only the infrequent cells with high CD25
expression have regulatory function (7). Alternatively, the more
abundant CD4⫹CD25⫺ T cells can be differentiated into
CD4⫹CD25⫹ T regs that express Foxp3 by stimulation with
mitogenic antibodies in the presence of TGF-␤1, although it is
not known whether these induced cells are functionally identical
to T regs that develop in the thymus (8). Such ‘‘induced T regs’’
with islet specificity can prevent diabetes in lymphopoenic
models (9), but their ability to induce tolerance at late pathogenic stages of autoimmunity, such as in already-diabetic NOD
mice, has not been fully addressed.
A separate issue that remains to be addressed is the requirement for APCs in the induction of T regs with TGF-␤1. The use
of DCs instead of mitogenic stimuli to differentiate T regs de
novo from CD4⫹CD25⫺ T cells has numerous potential advantages, including selection and maintenance of antigen specificity
(10, 11); provision of paracrine TGF-␤1 (12–14), which is known
to play an important role in T reg homeostasis by its ability to
induce Foxp3 (8, 15); and/or provision of costimulatory signals
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0611646104

such as CD80/86 for CTLA-4 ligation, which is necessary for
TGF-␤1-dependent induction of Foxp3 (16, 17).
In this study, we examined the ability of DCs from NOD mice
to induce islet antigen-specific CD4⫹CD25⫹Foxp3⫹ T cells from
naive CD4⫹CD25⫺Foxp3⫺ T cells. By using T cells from BDC2.5
mice, a well described diabetogenic CD4⫹ TCR transgenic
system (18), we show that DCs, together with specific peptide
and TGF-␤1, induce CD4⫹CD25⫹Foxp3⫹ T cells that maintain
islet-antigen specificity. The stimulation with DCs and TGF-␤1
results in T cells that have high levels of Foxp3 as well as specific
TCR expression, and these T cells are able to suppress proliferation and cytokine responses in vitro. Importantly, the
DC⫹TGF-␤1-induced CD4⫹CD25⫹Foxp3⫹ T cells also are
potent suppressors of ongoing autoimmune diabetes in vivo and
provide significant protection for syngeneic islet grafts in diabetic mice from established autoimmune destruction.
Results
Splenic CD11cⴙ DCs Induce Differentiation of CD4ⴙCD25ⴙFoxp3ⴙ T
Regs in the Presence of TGF-␤1. To test the role of DCs in the de

novo differentiation of CD4⫹CD25⫹Foxp3⫹ T regs, we used
CD4⫹CD25⫺ T cells from the BDC2.5 TCR transgenic NOD
mice. These T cells respond to both an unidentified autoantigen
expressed in the secretory granules of islet ␤ cells and a
mimetope peptide (BDC) (18, 19). We isolated CD11c⫹ DCs
from splenocytes of NOD mice and characterized them for
expression of CD40, CD86, and MHCII (Fig. 1A). Compared
with LPS-matured DCs, these freshly isolated DCs express
weaker CD40 and MHC II and significantly less CD86 (data not
shown), suggesting a relatively immature phenotype. We also
characterized a starting population of CD4⫹CD25⫺CD62L⫹
BDC2.5 T cells, after FACS sorting to a purity of ⬎95%, and
found the expected small fraction of Foxp3⫹ cells (Fig. 1B). We
then added the DCs together with the BDC peptide to the
CD4⫹CD25⫺ BDC2.5 T cells in the presence or absence of
TGF-␤1. After 6 days of culture, we saw good induction of Foxp3
mRNA (Fig. 1D) and protein (Fig. 1B), but only when TGF-␤1
was included in the cultures. In the presence of TGF-␤1, the
frequency of Foxp3⫹ cells increased to 88.3 ⫾ 7% (n ⫽ 3; Fig.
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CD4ⴙCD25ⴙFoxp3ⴙ regulatory T cells (T regs) are important for
preventing autoimmune diabetes and are either thymic-derived
(natural) or differentiated in the periphery outside the thymus
(induced). Here we show that ␤-cell peptide-pulsed dendritic cells
(DCs) from nonobese diabetic (NOD) mice can effectively induce
CD4ⴙCD25ⴙFoxp3ⴙ T cells from naı̈ve islet-specific CD4ⴙCD25ⴚ T
cells in the presence of TGF-␤1. These induced, antigen-specific T
regs maintain high levels of clonotype-specific T cell receptor
expression and exert islet-specific suppression in vitro. When
cotransferred with diabetogenic cells into NOD scid recipients, T
regs induced with DCs and TGF-␤1 prevent the development of
diabetes. Furthermore, in overtly NOD mice, these cells are able to
significantly protect syngeneic islet grafts from established destructive autoimmunity. These results indicate a role for DCs in the
induction of antigen-specific CD4ⴙCD25ⴙFoxp3ⴙ T cells that can
inhibit fully developed autoimmunity in a nonlymphopoenic host,
providing an important potential strategy for immunotherapy in
patients with autoimmune diabetes.

A

isotype control

Foxp3

B

100

100

80

80

% 60
of
Max 40

% 60
of
40
Max

CD25

20
0

0.18

1.3

95%

20
0

10 0

10 1

10 2

103

10 4

CD40

MCH II (I-Ag7)

CD86

– TGF-β1

10 4

11

10 0

+ TGF-β1

10 1

10 2

10 3

10 4

CD62L FITC

10 3

94

10 1

88

2.7

10 2

10 0
10 0

10 1

10 2

10 3

10 4

Foxp3

C
33,312

30000

Number
of
Foxp3
cells
per well

27,375
20000

22,875

21,000

10000

6625
1866

0
10 4

40

20

6.2

3.4

3.3

1.5

88

10 3

10 2

10 1

CD25

10 0

71

24
10 0

10 1

10 2

2

10 3

10 4

82

3

88

4

86

5

96

6

0.43

10

isotype
control

Days of culture

Foxp3

D

E

P=0.749

0 ng/ml

0.01 ng/ml

96

P=0.012

58

120

3.1

Foxp3
mRNA
level
80
(fold
increase)

10 4

0.02 ng/ml
56

42

15

8.1

0.1 ng/ml
18

43

81

7.6

10 3

40

10 2

CD25

0

+TGFβ1

–TGFβ1

Natural
CD25+

85

10 1

10 0
10 0

Foxp3

10 1

10 2

0.2 ng/ml

10 3

91

92

1.0 ng/ml

2.0 ng/ml

10 4

99.7

0.12
isotype
control

Downloaded at Rockefeller University Library on August 17, 2020

Fig. 1. Splenic DCs efficiently induce Foxp3 expression from naı̈ve CD4⫹CD25⫺ T cells. (A) Cell surface expression of CD40, CD86, and MHC class II (I-Ag7) of freshly
isolated NOD splenic CD11c⫹ DCs. (B) Foxp3 expression by precultured sorted CD4⫹CD25⫺CD62L⫹ BDC2.5 T cells and induction in T cells after culture with or
without 2 ng/ml TGF-␤1 on day 6 of culture. Expression of CD62L by precultured CD4⫹CD25⫺ BDC2.5 T cells is also shown. (C) Time-course of induction of
CD4⫹CD25⫹Foxp3⫹ BDC2.5 T cells from naı̈ve CD4⫹CD25⫺Foxp3⫺ BDC2.5 T cells in the presence of 2 ng/ml TGF-␤1. (Upper) Total number of Foxp3⫹ T cells per
well. (Lower) Percentages of Foxp3⫹ T cells determined by intracellular staining on days 2, 3, 4, 5, 6, and 10 of DC-T cultures. The isotype control for day 3 is shown.
(D) Quantification of Foxp3 mRNA by real-time RT-PCR. Samples were prepared from enriched CD25⫹ fractions of the resulting T cells from cocultures with or
without 2 ng/ml TGF-␤1 or freshly isolated CD4⫹CD25⫹ and CD4⫹CD25⫺ BDC2.5 T cells. Values were standardized by 18s RNA and expressed as fold of increase
compared with precultured freshly isolated CD4⫹CD25⫺ cells. (E) Dose-response of TGF-␤1 determined on day 6 of DC-T cocultures at indicated concentrations
of TGF-␤1. The isotype control for the 0.01 ng/ml dose is shown. All results are representative of two to four separate experiments.

1B), and their numbers increased ⬇50- to 100-fold (Fig. 1C). The
newly formed Foxp3⫹ cells appeared by 2 days of culture, and the
total number of Foxp3⫹ cells peaked at 4 days and decreased
after 6 days. Because of the rapid appearance of the Foxp3⫹
cells, the increase observed is unlikely to be caused by the
2822 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0611646104

expansion of the few Foxp3⫹ cells in the starting population. In
the absence of TGF-␤1, the percentage of Foxp3⫹ cells remained
close to baseline, although CD25 expression was still induced
(Fig. 1B). Quantification of Foxp3 mRNA expression by realtime RT-PCR demonstrated that the level induced by the DCs
Luo et al.
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Fig. 2. Characterization of CD4⫹CD25⫹Foxp3⫹ BDC T cells induced by DCs and TGF-␤1. (A) Intracellular expressions of IFN-␥, IL-10, and IL-17 on day 6 of DC-T
coculture. The addition of 20 ng/ml IL-6 induced IL-17 expression. (B) Expression of CD62L, CTLA-4, and GITR on day 6 of DC-T coculture. Cells cultured in the
absence of TGF-␤1 were also shown for comparison. Shaded histogram, isotype control; blue line, ⫹TGF-␤1; red dotted line, ⫺TGF-␤1. (C) BDC clonotype
expression. (Left) Freshly isolated BDC2.5 CD4⫹ T cells. (Right) T cells on day 6 after culture. Shaded histogram, isotype control; blue line, T cells cultured with
DCs and TGF-␤1; green line, T cells cultured with anti-CD3, anti-CD28, and TGF-␤1. All results are representative of two to four separate experiments.

Characterization of CD4ⴙCD25ⴙFoxp3ⴙ T Regs Induced by DCs and
TGF-␤1. We next determined cytokine expression by T cells

Downloaded at Rockefeller University Library on August 17, 2020

cultured with splenic DCs and TGF-␤1. No IFN-␥ or IL-10 was
observed (Fig. 2A). Because TGF-␤1 is able to induce IL-17secreting cells or Foxp3⫹ cells depending on the presence or
absence of IL-6 (20), we also tested IL-17 production. T cells
cultured with splenic DCs and TGF-␤1 were negative for IL-17
expression, whereas as a positive control, T cells cultured with
IL-6 and TGF-␤1 did express IL-17 (Fig. 2 A).
Next, we assessed the expression of proteins associated with T
reg function in the CD4⫹CD25⫹Foxp3⫹ T cells differentiated by
splenic DCs and TGF-␤1. As shown in Fig. 2B, a greater
percentage of T cells cultured in the presence of TGF-␤1
retained CD62L expression compared with those cultured in the
absence of TGF-␤1. T cells cultured either with or without
TGF-␤1 up-regulated both CTLA-4 and glucocorticoid-induced
TNF receptor (GITR; Fig. 2B), whereas freshly purified T cells
were negative for both (data not shown).
Because the level of TCR expression contributes to the avidity
of T cell responses, we measured BDC clonotype expression
before and after stimulation. Approximately 90% of freshly
isolated CD4⫹ BDC2.5 T cells were clonotype⫹ (Fig. 2C).
Stimulation with splenic DCs pulsed with the BDC peptide
maintained high levels of clonotype expression. In contrast,
nonspecific stimulation with anti-CD3/CD28 resulted in much
lower clonotype expression (Fig. 2C). These observations indicate that the DC and TGF-␤1-induced T regs share many
features with natural T regs.
In Vitro Suppression of CD4ⴙCD25ⴙFoxp3ⴙ T Regs Induced by DCs and
TGF- ␤ 1. To test for the suppressive function of the

CD4⫹CD25⫹Foxp3⫹ T cells induced with splenic DCs and
TGF-␤1, we first used an in vitro assay. We depleted CD11c⫹
cells and enriched the CD25⫹ T cell fraction from 6-day cultures
with DCs and added the resulting CD4⫹CD25⫹ T cells in graded
doses to responder CD4⫹CD25⫺ BDC2.5 T cells. We then
Luo et al.

measured the inhibition of proliferation to BDC peptide presented by whole NOD splenic APCs. As shown in Fig. 3A, in the
presence of TGF-␤1, the DC-induced CD4⫹CD25⫹ T cells were
91% Foxp3⫹ after enrichment. They were anergic in response to
BDC peptide and were able to block the proliferation of naı̈ve
BDC2.5 T cells to BDC peptide (70% suppression at a 1:1 ratio).
This ratio of T regs needed for suppression was greater than
required for DC-expanded natural T regs, which gave similar
suppression of proliferation with 4-fold fewer T regs (4). Suppression of IFN-␥ secretion was also observed and at a responder/suppressor ratio as low as 8:1 (Fig. 3A). In contrast, in the
absence of TGF-␤1, the resulting CD4⫹CD25⫹ T cells were only
11% Foxp3⫹ after enrichment. They showed vigorous proliferation to BDC peptide themselves, were unable to suppress
proliferation of naı̈ve BDC2.5 T cells, and led to augmented
IFN-␥ secretion (Fig. 3B). Therefore, the induced Foxp3⫹ T regs
have some suppressive function in vitro, although they are less
potent than natural T regs after expansion with DCs (4).
CD4ⴙCD25ⴙFoxp3ⴙ T Regs Induced by DCs and TGF-␤1 Suppress
Autoimmune Diabetes in Vivo. A more critical function for natu-

rally occurring CD4⫹CD25⫹ T regs is the suppression of autoimmunity in vivo. To test whether the T regs induced by splenic
DCs and TGF-␤1 could inhibit autoimmune diabetes, we first
used adoptive transfer in NOD.scid recipients. In this model,
injection of diabetogenic splenocytes from acutely diabetic NOD
mice into NOD.scid recipients results in rapid autoimmune
destruction of the native pancreas and consequent development
of hyperglycemia (21). Because a known quantity of diabetogenic splenocytes is injected into the NOD.scid recipients, this
model allows for a measurement of the potency of the DCinduced T regs according to the kinetics of diabetes development
after injection. As shown in Fig. 4, i.v. coinjection of 3 ⫻ 105 of
the DC⫹TGF-␤1-induced CD4⫹CD25⫹ T cells along with 107
diabetogenic splenocytes resulted in complete protection from
the development of diabetes (0/6 recipients developed diabetes
at 120 days after injection). In addition, 10-fold fewer (3 ⫻ 104)
of the same T cells coinjected with 107 diabetogenic splenocytes
still resulted in a significant delay of onset and a lower incidence
of diabetes. In contrast, injection of either dose of the
CD4⫹CD25⫹ T cells from cultures without TGF-␤1 along with
107 diabetogenic splenocytes resulted in accelerated onset of
diabetes in NOD.scid recipients.
PNAS 兩 February 20, 2007 兩 vol. 104 兩 no. 8 兩 2823

IMMUNOLOGY

and TGF-␤1 was equivalent to that found in naturally occurring
T regs (Fig. 1D). The induction of Foxp3⫹ cells by TGF-␤1 was
dose-dependent, being readily evident at 0.01 ng/ml and peaking
at 1 ng/ml (Fig. 1E). Therefore, DCs can serve as effective APCs
for differentiating Foxp3⫹ T cells from CD4⫹CD25⫺Foxp3⫺
precursors in the presence of low-dose TGF-␤1.
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Fig. 3. CD4⫹CD25⫹Foxp3⫹ BDC T cells induced by DCs and TGF-␤1 suppress BDC-specific T cell proliferation and cytokine production. After 6 days of culture
with (A) or without (B) TGF-␤1, CD11c⫹ cells were depleted and CD25⫹ cells were enriched. FACS plots constructed after the enrichment are shown (Left).
Proliferation assays were set up with CD4⫹CD25⫺ cells from BDC2.5 mice [responders (R)], APCs from NOD mice, and BDC peptide (100 ng/ml). Increasing numbers
of the induced CD4⫹CD25⫹ cells [suppressors (S)] were added at ratios indicated. Proliferation was assessed by [3H]thymidine uptake (Center), and IFN-␥ was
measured from culture supernatants (Right) as described in Materials and Methods.

Next, we tested the efficacy of these T regs in blocking
autoimmune destruction of a syngeneic islet graft in spontaneously diabetic NOD recipients. This model represents a clinically
relevant scenario of diabetes pathogenesis in which islet-specific
effector cells are already present in a nonlymphopoenic host.
Without intervention, ongoing autoimmunity directed toward
the transplanted islet ␤ cells results in graft destruction within
5–17 days after transplantation (22). To avoid the confounding
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Time post transfer (days)
Fig. 4. CD4⫹CD25⫹Foxp3⫹ BDC T cells induced by DCs and TGF-␤1 block the
development of diabetes in NOD.scid recipients. NOD.scid mice were injected
i.v. with 107 spleen cells from diabetic NOD females with either nothing (red
triangles) or the indicated numbers of CD4⫹CD25⫹ BDC T cells from cultures
with splenic DCs in the presence (⫹TGF-␤1 BDC T, blue circles) or absence
(⫺TGF-␤1 BDC T, green squares) of TGF-␤1. P ⬍ 0.0001, control vs. 3 ⫻ 105
⫹TGF-␤1 BDC T cells; P ⬍ 0.0001, control vs. 3 ⫻ 104 ⫹TGF-␤1 BDC T cells.
2824 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0611646104

factor of T reg cell trafficking, we chose to directly deposit the
T regs at the site of the islet graft, i.e., the kidney subcapsular
space. When we cotransplanted 3 ⫻ 105 DC⫹TGF-␤1-induced
CD4⫹CD25⫹ T cells along with the syngeneic islets into the
kidney subcapsular space of diabetic NOD recipients, there was
a significant prolongation of graft survival (Fig. 5). In contrast,
CD4⫹CD25⫹ T cells induced in the absence of TGF-␤1accelerated isograft destruction.
In both the adoptive transfer NOD.scid model and the spontaneous diabetes NOD model, the CD4⫹CD25⫹Foxp3⫹ T regs
induced by DCs and TGF-␤1 were therefore able to effectively
block autoimmunity mediated by a diverse repertoire of autoreactive TCR specificities, analogous to the previously reported
properties of ‘‘natural’’ T regs.
Discussion
In this study, we have shown two unique findings: (i) DCs can
differentiate Foxp3⫺ cells en masse to Foxp3⫹ cells ex vivo in the
presence of TGF-␤1 and (ii) in vivo, islet-specific T regs differentiated with DCs and TGF-␤1 can protect islet grafts from
established destructive autoimmunity in diabetic NOD mice.
Demonstration of the in vivo potency of the DC⫹TGF-␤1induced T regs in the NOD model is important because although
these ex vivo-induced T regs express similar levels of Foxp3 as the
thymic-derived T regs, they may not be functionally identical a
priori. In fact, the in vitro suppression of T regs induced with DCs
and TGF-␤1 is not as potent as previously observed with natural
T regs (Fig. 3 and ref. 4). This finding suggests that factors other
than Foxp3 expression levels may be important for T reg
function. Here we show that despite this decreased in vitro
potency, DC⫹TGF-␤1-induced T regs with islet specificity can
suppress pathogenic T cells of other specificities and inhibit
diabetes development, as had been shown for naturally occurring
T regs (4, 23).
Identifying DCs as an APC population for differentiation of
regulatory cells has important implications both for understanding of the basic biology of how T regs may be induced in vivo and
for the ability to translate this system for clinical applications. A
recent study reports that the targeted delivery of antigen to DCs
in vivo induces de novo differentiation of CD4⫹CD25⫹Foxp3⫹
Luo et al.
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Fig. 5. CD4⫹CD25⫹Foxp3⫹ BDC T cells induced by DCs and TGF-␤1 protect
syngeneic islet grafts from ongoing autoimmune destruction in spontaneously diabetic NOD recipients. A total of 500 NOD islets were transplanted into
kidney subcapsular space either alone (red) or with 3 ⫻ 105 ⫹TGF-␤1 BDC T
cells (blue) or ⫺TGF-␤1 BDC T cells (green). Day 0 indicates the day of islet
transplantation. (A) Blood glucose levels post transplantation. Each line represents one mouse. (B) Summary of graft survival after transplantation for
individual mice is shown in (A). P ⬍ 0.0001 for comparison of graft survival
among all three groups; P ⫽ 0.0069, ⫺TGF-␤1 BDC T vs. islets only; P ⫽ 0.0001,
⫹TGF-␤1 BDC T vs. islets only. Data represent the combination of three
separate transplant experiments with cells from three separate cultures.

cells from naı̈ve CD4⫹CD25⫺Foxp3⫺ T cells (24). Although this
approach provides a limited yield of T regs and has not yet been
used to suppress autoimmune disease, it suggests that the process
we are describing here with DCs and TGF-␤1 in vitro also occurs
in vivo. DCs presenting antigen induce effector cells, but here we
show that the addition of one cytokine, TGF-␤1, shifts the
differentiation to suppressor cells. With the system described
here, we can now define molecular signals that DCs may provide
to ensure efficient TGF-␤1-mediated induction of Foxp3.
Antigen-specific T regs are more potent suppressors of autoimmunity than polyclonal T regs; therefore, methods for the
expansion of islet-specific T regs will likely contribute to human
therapy of type 1 diabetes. Direct injection of either DCs from
pancreatic draining lymph nodes or ␤ cell antigen-pulsed immature DCs has been shown to protect prediabetic NOD
recipients from developing diabetes, possibly through the in vivo
induction of regulatory T cells (25, 26). In vitro, beads coated
Luo et al.

with complexes of islet peptide-MHC class II molecules can
expand islet-specific CD4⫹CD25⫹ T regs from a polyclonal
NOD T reg population (6). However, the lack of defined
peptides in the human disease may limit this approach. Conditions that would allow islet-loaded DCs to selectively enrich
islet-specific T regs from autoimmune individuals should be
investigated.
In allogeneic transplantation models, donor-specific T regs
also have been shown to mediate transplant tolerance and to
prevent graft rejection (27). Studies with therapeutic manipulations of transplant recipients have shown in vivo generation
and/or expansion of alloantigen-specific T regs as a potential
mechanism for transplant tolerance induction (28). An important difference between alloimmune and autoimmune tolerance
induction is that alloreactive T cells are found at greater initial
frequencies than autoreactive T cells, presumably because of
cross-reactivities between numerous allo-MHC peptide complexes and self-MHC molecules. Consequently, T reg therapies
in transplant models, such as skin allograft and graft-versus-host
disease models, typically required large numbers (106 to 107) of
T regs to achieve alloantigen-specific suppression in vivo (29–
31). Therefore, strategies to expand T regs may also be important
for the treatment of transplant rejection. The role of DCs in the
ex vivo expansion of donor-specific T regs only recently has
begun to be elucidated (11). Early studies have reported that the
injection of donor MHC class I allopeptide-pulsed host DCs
prolong the survival of rat islet allografts (32) and have implicated CD4⫹CD25⫹ T regs in the salutary effect on graft survival
(33). The system we describe here, in which we use DCs and
TGF-␤1 to differentiate large numbers of antigen-specific
CD4⫹CD25⫹Foxp3⫹ T regs, also may provide a clinically applicable tool for cell therapy in transplant tolerance induction.
In summary, our findings show that DCs can be harnessed for
efficient ex vivo differentiation of islet-specific CD4⫹CD25⫹
Foxp3⫹ T regs from naı̈ve CD4⫹CD25⫺ T cells. Therapy with
such ex vivo-generated T regs may provide additional treatments
for autoimmune diseases and for transplantation rejection (34).
Materials and Methods
Mice. NOD, NOD.scid, and BDC2.5 TCR transgenic mice were

purchased from The Jackson Laboratory (West Grove, PA).
Mice were used according to institutional guidelines and protocols approved by the institutional Animal Care and Use Committees at Northwestern University, Cornell University, and The
Rockefeller University.
Antibodies. Biotinylated mAbs for CD8 (53–6.7), CD25 (7D4),

Ly-76 (Ter-119), Gr1 (RB6–8C5), CD49b/Pan-NK (DX5), B220
(RA3–682), and CD11b (M1/70); FITC-conjugated anti-CD4
(GK1.5), CD11c (HL3), I-Ag7 (OX-6); PE-conjugated anti-IL-17
(TC11–18H10), IL-10 (JES5–16E3), CD25 (PC61), CD86
(GL1), GITR (DTA-1); and APC-conjugated anti-CD62L
(MEL-14) were from BD Biosciences (Franklin Lakes, NJ).
PE-conjugated anti-CD152 (UC10–4B9) and Foxp3 (FJK-16s)
in addition to APC-conjugated anti-CD25 (PC61) were from
eBioscience (San Diego, CA). A hybridoma expressing the
anti-clonotype antibody that is specific for BDC2.5 TCR (BDC)
was provided by O. Kanagawa (Washington University, St.
Louis, MO), and the antibody was purified and biotinylated (35).
Recombinant human TGF-␤1 was obtained from R&D Systems,
(Minneapolis, MN).
Cell Purifications. Splenic DCs were isolated from NOD males as
described in ref. 36. In brief, spleens from normoglycemic NOD
males between the ages of 4 and 10 weeks were first digested with
collagenase D (Sigma–Aldrich, St. Louis, MO) followed by the
enrichment of the DC fraction with 30% BSA density gradient.
The CD11c fraction was then purified with magnetic microbeads
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(Miltenyi Biotec, Auburn, CA). The purity of DCs was routinely
⬎90%. DCs were irradiated with 15 Gy before their use as APCs.
Naı̈ve CD4⫹CD25⫺ cells were purified from BDC2.5 spleen and
lymph nodes. Cells were first enriched by depletion (anti-CD8,
CD25, Ter119, Gr1, DX5, B220, CD11b) followed by FACS
sorting for the CD4⫹CD25⫺CD62L⫹ population to ⬎95% purity.
Cell Culture, Proliferation Assays, and Cytokine Detection. The sequence of the mimetope peptide used (BDC) was RVRPLWVRME (18). A total of 2 ⫻ 104 per well of CD4⫹CD25⫺BDC2.5
T cells were cultured for 6–10 days with splenic DCs at a 3:1 T/DC
cell ratio in 96-well plates with 100 ng/ml BDC peptide, either with
or without TGF-␤1 at indicated concentrations. Alternatively, T
cells were cultured with 10 g/ml anti-CD3 (a gift from Terrence
Barrett, San Jose, CA) and 2 g/ml anti-CD28 (BD Biosciences,
San Jose, CA) for 6 days. For functional tests, DCs were removed
by CD11c antibody-conjugated magnetic microbeads, and CD25⫹
cells were further enriched by labeling them with PE-conjugated
anti-CD25 (PC61) and anti-PE microbeads. For proliferation assays, freshly isolated CD4⫹CD25⫺ BDC2.5 T cells were cultured
with NOD whole spleen cells at a T/APC cell ratio of 1:5 and 100
ng/ml BDC peptide. [3H]thymidine (1 Ci per well; PerkinElmer,
San Jose, CA) was added for the last 18 h of a 72-h assay. For
suppression assays, the cultured CD25⫹ T cells were added to
proliferation assays at the indicated ratios and [3H]thymidine
uptake was measured. For cytokine assays, culture supernatants
were tested with the LiquiChip Mouse 10-cytokine assay kit (Qiagen, Valencia, CA). For intracellular cytokine detection, cells were
first stimulated with leukocyte activation mixture (BD Biosciences)
for 4 h before being stained in accordance with the manufacturer’s
protocol.

Diabetes Experiments. For NOD.scid experiment, diabetes was
induced in 5- to 9-week-old NOD.scid mice with an i.v. injection of
107 spleen cells from female NOD mice with diabetes. Indicated
numbers of the induced CD4⫹CD25⫹ T cells were coinjected where
indicated. Urine glucose was checked two to three times per week,
and the development of diabetes in NOD.scid mice was defined as
three consecutive positive urine glucose readings.
The spontaneous development of diabetes in female NOD
mice was defined as two consecutive blood glucose levels of
⬎250 mg/dl. Islet isolation and transplantation were performed
as described in ref. 22. In brief, islets were handpicked to a purity
of ⬎80% for transplant, and 500–600 islets were transplanted
into the kidney subcapsular space of newly diabetic NOD female
mice. For cell and islet cotransplants, the indicated numbers of
T cells were mixed with islets immediately before transplantation. Graft destruction was diagnosed by the recurrence of
hyperglycemia (blood glucose level ⬎250 mg/dl on two consecutive readings).
Statistical Analysis. For analysis of real-time PCR data, we used

the Student’s t test. To analyze the incidence of diabetes in
NOD.scid and syngeneic islet graft survival in NOD recipients,
we used analysis of variance. We considered P ⬍ 0.05 to be
significant.

(Qiagen). The sequences of primers and probe for mouse Foxp3
were as follows: sense 5⬘-AGGAGAAGCTGGGAGCTATGC-
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Real-Time PCR. Total RNA was extracted with the RNeasy mini kit
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3⬘; anti-sense 5⬘-TGGCTACGATGCAGCAA GAG-3⬘; probe
5⬘-FAM AGCGCCATCTTCCCAGCCAGG TAMRA-3⬘. The
final quantity of mRNA was calculated as copies per microgram
of RNA and standardized according to 18s RNA.
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